Literature DB >> 2156441

IGF-II receptors and IGF-II-stimulated glucose transport in human fat cells.

M K Sinha1, C Buchanan, C Raineri-Maldonado, P Khazanie, S Atkinson, R DiMarchi, J F Caro.   

Abstract

Insulin-like growth factor II (IGF-II) receptors have been described in rat but not in human adipocytes. In both species, IGF-II has been reported to stimulate glucose transport by interacting with the insulin receptor. In this study, we have unequivocally demonstrated the presence of IGF-II receptors in human adipocytes. 125I-labeled IGF-II specifically binds to intact adipocytes, membranes, and lectin-purified detergent solubilized extracts. Through the use of 0.5 mM disuccinimidyl suberate, 125I-IGF-II is cross-linked to a 260-kDa protein that is identified as the IGF-II receptor by displacement experiments with unlabeled IGF-II, IGF-I, and insulin and either by immunoprecipitation or by Western blot analysis with mannose 6-phosphate receptor antibodies. The concentrations of IGF-II required for half-maximal and maximal stimulation of glucose transport in human adipocytes are 35 and 100 times more than that of insulin. The possibility of IGF-II stimulating glucose transport by interacting predominantly with the insulin receptor is suggested by the following: 1) the concentration of IGF-II that inhibits half of insulin binding is only 20 times more than that of insulin; 2) the lack of an additive effect of IGF-II and insulin for maximal stimulation of glucose transport; 3) the ability of monoclonal insulin receptor antibodies to decrease glucose transport stimulated by submaximal concentrations of both IGF-II and insulin; and 4) the ability of IGF-II to stimulate insulin receptor autophosphorylation albeit at a reduced potency when compared with insulin.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2156441     DOI: 10.1152/ajpendo.1990.258.3.E534

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  8 in total

1.  Acute actions of insulin-like growth factor II on glucose metabolism in adult rats.

Authors:  F Stümpel; H Hartmann
Journal:  Diabetologia       Date:  1992-10       Impact factor: 10.122

2.  Establishment of a xeno-free culture system that preserves the characteristics of placenta mesenchymal stem cells.

Authors:  Saeyoung Park; Hye-Ran Park; Won-Don Lee; Chang-Young Hur; Young-Jay Lee
Journal:  Cytotechnology       Date:  2014-07-06       Impact factor: 2.058

3.  Insulin-like Growth Factor 2 Promotes Tissue-Specific Cell Growth, Proliferation and Survival during Development of Helicoverpa armigera.

Authors:  Yu-Meng Zhao; Xiao-Pei Wang; Ke-Yan Jin; Du-Juan Dong; Tobias Reiff; Xiao-Fan Zhao
Journal:  Cells       Date:  2022-05-31       Impact factor: 7.666

4.  Metabolic actions of insulin-like growth factor II in cultured adult rat hepatocytes are not mediated through the insulin-like growth factor II receptor.

Authors:  H Hartmann; A Meyer-Alber; T Braulke
Journal:  Diabetologia       Date:  1992-03       Impact factor: 10.122

5.  Stimulation of glucose uptake by insulin-like growth factor II in human muscle is not mediated by the insulin-like growth factor II/mannose 6-phosphate receptor.

Authors:  B Burguera; C W Elton; J F Caro; E B Tapscott; W J Pories; R Dimarchi; K Sakano; G L Dohm
Journal:  Biochem J       Date:  1994-06-15       Impact factor: 3.857

6.  Insulin-like growth factor-II in adipocyte regulation: depot-specific actions suggest a potential role limiting excess visceral adiposity.

Authors:  Maiadah N Alfares; Claire M Perks; Julian P Hamilton-Shield; Jeffrey M P Holly
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-07-24       Impact factor: 4.310

7.  Insulin-like growth factor-II: new roles for an old actor.

Authors:  Stefano Cianfarani
Journal:  Front Endocrinol (Lausanne)       Date:  2012-10-02       Impact factor: 5.555

8.  Case Report: Liraglutide for Weight Management in Beckwith-Wiedemann Syndromic Obesity.

Authors:  Marina Caputo; Tommaso Daffara; Simonetta Bellone; Valentina Mancioppi; Paolo Marzullo; Gianluca Aimaretti; Flavia Prodam
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-22       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.